Modulating the Locus Coeruleus Function

Healthy Aging Clinical Trial

Official title:

Boosting a Neuromodulatory System Relevant to Alzheimer's Disease to Enhance Memory

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04877782
• Other study ID #: NL77066.068.21
• Status: Completed
• Start date: January 14, 2021
• Est. completion date: October 5, 2023

Study information

• Verified date: October 2023
• Source: Maastricht University Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to investigate the impact of transcutaneous vagus nerve stimulation (tVNS) on specific brain regions involved in memory and attention processes.

tVNS is a non-invasive and non-pharmacological technique known for targeting the locus coeruleus, a small subcortical nucleus in the brain thought to be involved in the earliest stages of Alzheimer's disease. This nucleus also plays a role in numerous cognitive functions, comprising memory and attention.

Description:

This study is an observational MRI study with a pseudo-randomized single blind cross-over design. The population consists of 30 healthy human volunteers from 60 to 80 years old. These healthy older individuals will be recruited from the community.

After being informed about the study protocol and the potential risks, subjects will be given 1 week to consider their participation.

All participants giving written informed consent will be included in the study. The first session will consist in neuropsychological assessments and a task practice session in the dummy scanner in order to get familiar with the environment. Participants meeting the eligibility criteria will be included for the next sessions.

The second and third sessions are MRI scanning sessions including transcutaneous vagus nerve stimulation. Both the placebo and experimental stimulation conditions will be randomized in a single-blind manner across scanning sessions.

About 7 to 10 weeks after each scanning session and at least 4 days previous to the next MRI session, participant will be asked to fill in an online memory test for assessing potential outlasting effects of the stimulation technique.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: October 5, 2023
• Est. primary completion date: September 25, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 60 Years to 80 Years

Eligibility

Inclusion Criteria:

• Average neuropsychological test results in accordance with normative data corrected for age, education and sex

• No substantial memory complaints according to the participant

• Body mass index < 28

• Non-smoking

• Right handedness

• Average/high level of education (minimum 12 years of education)

Exclusion Criteria:

• Psychoactive medication use

• Abuse of alcohol and drugs

• Cognitive impairment due to alcohol/drug or other substances abuse

• Recent trans-meridian travel (<2months)

• Night shift work (<1year)

• Diabetes if not stable

• Hypo-/hyper-tension, hypo-/hyper-thyroid if not stable

• Hypo-tension due to autonomic dysfunction

• Recent (<5years) or present psychiatric or neurological disorders (anxiety, major depression, schizophrenia, bipolar disorder, psychotic disorder -or treatment for it-, epilepsy, stroke, Alzheimer's disease, Parkinson's disease, multiple sclerosis, brain surgery, brain trauma, electroshock therapy, kidney dialysis, Ménière's disease, brain infections)

• Major vascular disorders (e.g. stroke)

• History of cardiovascular disorders (e.g., severe heart failure, recurrent vasovagal syncopal episodes)

• Major valvular disorders (e.g., prosthetic valve or hemodynamically relevant valvular disease, unilateral or bilateral vagotomy)

• Contraindications for scanning (e.g., brain surgery, cardiac pacemaker, metal implants, claustrophobia, body tattoos, reduced vision even after appropriate optical correction)

• Contraindications for pupil measurements and light exposure (e.g., Cataracts, Glaucoma, detached retina's, eye surgery involving the muscle, penetrating eye wounds, use of cholinesterase inhibitors, anticholinergic eye drop use, droopy eyelids preventing eye measurement).

Related Conditions & MeSH terms

• Healthy Aging

Intervention

Device:
• Transcutaneous vagus verne stimulation
Non-invasive and short electrical stimulation by placing the stimulating electrode at the cymba conchae of the left ear. The reference electrode is placed near the left cymba conchae. It provides a light tingling, massaging feeling in the ear.

Locations

Country	Name	City	State
Netherlands	Maastricht University	Maastricht

Sponsors (2)

Lead Sponsor	Collaborator
Maastricht University Medical Center	University of Liege

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pupillometry - Scan session 1	Measure of pupil size variations during functional tasks. It can be used as a proxy for measuring arousal-related state transitions in brain activity and it allows for a reliable detection of the locus coeruleus activity.	During the first MRI scanning session (55 minutes)
Primary	Pupillometry - Scan session 2	Measure of pupil size variations during functional tasks. It can be used as a proxy for measuring arousal-related state transitions in brain activity and it allows for a reliable detection of the locus coeruleus activity.	During the second MRI scanning session (55 minutes)
Primary	Blood oxygen level dependent (BOLD) response - Scan session 1	This BOLD signal reflects brain activity during the functional tasks. The study focuses on the BOLD-signal in the locus coeruleus and task-relevant networks during the memory and the vigilance tasks.	During the first MRI scanning session (55 minutes)
Primary	Blood oxygen level dependent (BOLD) response - Scan session 2	This BOLD signal reflects brain activity during the functional tasks. The study focuses on the BOLD-signal in the locus coeruleus and task-relevant networks during the memory and the vigilance tasks.	During the second MRI scanning session (55 minutes)
Secondary	Performance on the online memory task - Post-session 1	Total accuracy on the face-name association task (from 0 to 100%); Mean reaction time on the face-name association task (from 0 to 4 seconds).; The higher the total accuracy and the lower the mean reaction time, the better the outcome measure.	Performed from home, 7 to 10 days after the first MRI session and at least 4 days prior to the second session.
Secondary	Performance on the online memory task - Post-session 2	Total accuracy on the face-name association task (from 0 to 100%); Mean reaction time on the face-name association task (from 0 to 4 seconds).; The higher the total accuracy and the lower the mean reaction time, the better the outcome measure.	Performed from home, 7 to 10 days after the second MRI session.